Request for Covid-19 Impact Assessment of this Report

Healthcare

Global Neuroblastoma Treatment Drugs Market Growth 2022-2028

  • LP 4964195
  • 93 Pages
  • June 2022
  • Healthcare
Download Sample    Get Discount   
 
As the global economy mends, the 2021 growth of Neuroblastoma Treatment Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Neuroblastoma Treatment Drugs market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Neuroblastoma Treatment Drugs market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.

The United States Neuroblastoma Treatment Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Neuroblastoma Treatment Drugs market, reaching US$ million by the year 2028. As for the Europe Neuroblastoma Treatment Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.

Global main Neuroblastoma Treatment Drugs players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, and ANI Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Treatment Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

Cyclophosphamide

Dinutuximab

Naxitamab

Doxorubicin Hydrochloride

Vincristine Sulfate

Other

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Hospital

Clinic

Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer

Hikma Pharmaceuticals

Teva Pharmaceuticals

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neuroblastoma Treatment Drugs Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Country/Region, 2017, 2022 & 2028

2.2 Neuroblastoma Treatment Drugs Segment by Type

2.2.1 Cyclophosphamide

2.2.2 Dinutuximab

2.2.3 Naxitamab

2.2.4 Doxorubicin Hydrochloride

2.2.5 Vincristine Sulfate

2.2.6 Other

2.3 Neuroblastoma Treatment Drugs Sales by Type

2.3.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

2.3.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Type (2017-2022)

2.3.3 Global Neuroblastoma Treatment Drugs Sale Price by Type (2017-2022)

2.4 Neuroblastoma Treatment Drugs Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Other

2.5 Neuroblastoma Treatment Drugs Sales by Application

2.5.1 Global Neuroblastoma Treatment Drugs Sale Market Share by Application (2017-2022)

2.5.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Application (2017-2022)

2.5.3 Global Neuroblastoma Treatment Drugs Sale Price by Application (2017-2022)

3 Global Neuroblastoma Treatment Drugs by Company

3.1 Global Neuroblastoma Treatment Drugs Breakdown Data by Company

3.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Company (2020-2022)

3.1.2 Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2020-2022)

3.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Company (2020-2022)

3.2.1 Global Neuroblastoma Treatment Drugs Revenue by Company (2020-2022)

3.2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2020-2022)

3.3 Global Neuroblastoma Treatment Drugs Sale Price by Company

3.4 Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neuroblastoma Treatment Drugs Product Location Distribution

3.4.2 Players Neuroblastoma Treatment Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Neuroblastoma Treatment Drugs by Geographic Region

4.1 World Historic Neuroblastoma Treatment Drugs Market Size by Geographic Region (2017-2022)

4.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Geographic Region

4.2 World Historic Neuroblastoma Treatment Drugs Market Size by Country/Region (2017-2022)

4.2.1 Global Neuroblastoma Treatment Drugs Annual Sales by Country/Region (2017-2022)

4.2.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Country/Region

4.3 Americas Neuroblastoma Treatment Drugs Sales Growth

4.4 APAC Neuroblastoma Treatment Drugs Sales Growth

4.5 Europe Neuroblastoma Treatment Drugs Sales Growth

4.6 Middle East & Africa Neuroblastoma Treatment Drugs Sales Growth

5 Americas

5.1 Americas Neuroblastoma Treatment Drugs Sales by Country

5.1.1 Americas Neuroblastoma Treatment Drugs Sales by Country (2017-2022)

5.1.2 Americas Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)

5.2 Americas Neuroblastoma Treatment Drugs Sales by Type

5.3 Americas Neuroblastoma Treatment Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neuroblastoma Treatment Drugs Sales by Region

6.1.1 APAC Neuroblastoma Treatment Drugs Sales by Region (2017-2022)

6.1.2 APAC Neuroblastoma Treatment Drugs Revenue by Region (2017-2022)

6.2 APAC Neuroblastoma Treatment Drugs Sales by Type

6.3 APAC Neuroblastoma Treatment Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Neuroblastoma Treatment Drugs by Country

7.1.1 Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022)

7.1.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)

7.2 Europe Neuroblastoma Treatment Drugs Sales by Type

7.3 Europe Neuroblastoma Treatment Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Neuroblastoma Treatment Drugs by Country

8.1.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2017-2022)

8.1.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)

8.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type

8.3 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs

10.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs

10.4 Industry Chain Structure of Neuroblastoma Treatment Drugs

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neuroblastoma Treatment Drugs Distributors

11.3 Neuroblastoma Treatment Drugs Customer

12 World Forecast Review for Neuroblastoma Treatment Drugs by Geographic Region

12.1 Global Neuroblastoma Treatment Drugs Market Size Forecast by Region

12.1.1 Global Neuroblastoma Treatment Drugs Forecast by Region (2023-2028)

12.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Neuroblastoma Treatment Drugs Forecast by Type

12.7 Global Neuroblastoma Treatment Drugs Forecast by Application

13 Key Players Analysis

13.1 United Therapeutics

13.1.1 United Therapeutics Company Information

13.1.2 United Therapeutics Neuroblastoma Treatment Drugs Product Offered

13.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 United Therapeutics Main Business Overview

13.1.5 United Therapeutics Latest Developments

13.2 Y-mAbs Therapeutics

13.2.1 Y-mAbs Therapeutics Company Information

13.2.2 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offered

13.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Y-mAbs Therapeutics Main Business Overview

13.2.5 Y-mAbs Therapeutics Latest Developments

13.3 EUSA Pharma

13.3.1 EUSA Pharma Company Information

13.3.2 EUSA Pharma Neuroblastoma Treatment Drugs Product Offered

13.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 EUSA Pharma Main Business Overview

13.3.5 EUSA Pharma Latest Developments

13.4 ANI Pharmaceuticals

13.4.1 ANI Pharmaceuticals Company Information

13.4.2 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

13.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 ANI Pharmaceuticals Main Business Overview

13.4.5 ANI Pharmaceuticals Latest Developments

13.5 Baxter Healthcare

13.5.1 Baxter Healthcare Company Information

13.5.2 Baxter Healthcare Neuroblastoma Treatment Drugs Product Offered

13.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Baxter Healthcare Main Business Overview

13.5.5 Baxter Healthcare Latest Developments

13.6 Ingenus Pharmaceuticals

13.6.1 Ingenus Pharmaceuticals Company Information

13.6.2 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

13.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Ingenus Pharmaceuticals Main Business Overview

13.6.5 Ingenus Pharmaceuticals Latest Developments

13.7 Pfizer

13.7.1 Pfizer Company Information

13.7.2 Pfizer Neuroblastoma Treatment Drugs Product Offered

13.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Pfizer Main Business Overview

13.7.5 Pfizer Latest Developments

13.8 Hikma Pharmaceuticals

13.8.1 Hikma Pharmaceuticals Company Information

13.8.2 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

13.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Hikma Pharmaceuticals Main Business Overview

13.8.5 Hikma Pharmaceuticals Latest Developments

13.9 Teva Pharmaceuticals

13.9.1 Teva Pharmaceuticals Company Information

13.9.2 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

13.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Teva Pharmaceuticals Main Business Overview

13.9.5 Teva Pharmaceuticals Latest Developments

14 Research Findings and Conclusion

List of Tables

Table 1. Neuroblastoma Treatment Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Neuroblastoma Treatment Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Cyclophosphamide

Table 4. Major Players of Dinutuximab

Table 5. Major Players of Naxitamab

Table 6. Major Players of Doxorubicin Hydrochloride

Table 7. Major Players of Vincristine Sulfate

Table 8. Major Players of Other

Table 9. Global Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)

Table 10. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

Table 11. Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2022) & ($ million)

Table 12. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)

Table 13. Global Neuroblastoma Treatment Drugs Sale Price by Type (2017-2022) & (US$/Unit)

Table 14. Global Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)

Table 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Table 16. Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2022)

Table 17. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2022)

Table 18. Global Neuroblastoma Treatment Drugs Sale Price by Application (2017-2022) & (US$/Unit)

Table 19. Global Neuroblastoma Treatment Drugs Sales by Company (2020-2022) & (K Units)

Table 20. Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2020-2022)

Table 21. Global Neuroblastoma Treatment Drugs Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2020-2022)

Table 23. Global Neuroblastoma Treatment Drugs Sale Price by Company (2020-2022) & (US$/Unit)

Table 24. Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution and Sales Area

Table 25. Players Neuroblastoma Treatment Drugs Products Offered

Table 26. Neuroblastoma Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Neuroblastoma Treatment Drugs Sales by Geographic Region (2017-2022) & (K Units)

Table 30. Global Neuroblastoma Treatment Drugs Sales Market Share Geographic Region (2017-2022)

Table 31. Global Neuroblastoma Treatment Drugs Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Neuroblastoma Treatment Drugs Sales by Country/Region (2017-2022) & (K Units)

Table 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Country/Region (2017-2022)

Table 35. Global Neuroblastoma Treatment Drugs Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)

Table 38. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)

Table 39. Americas Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)

Table 41. Americas Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)

Table 42. Americas Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

Table 43. Americas Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)

Table 44. Americas Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Table 45. APAC Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)

Table 46. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2022)

Table 47. APAC Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2022)

Table 49. APAC Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)

Table 50. APAC Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

Table 51. APAC Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)

Table 52. APAC Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Table 53. Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)

Table 54. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)

Table 55. Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)

Table 57. Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)

Table 58. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

Table 59. Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)

Table 60. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)

Table 62. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)

Table 66. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)

Table 68. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Neuroblastoma Treatment Drugs

Table 70. Key Market Challenges & Risks of Neuroblastoma Treatment Drugs

Table 71. Key Industry Trends of Neuroblastoma Treatment Drugs

Table 72. Neuroblastoma Treatment Drugs Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Neuroblastoma Treatment Drugs Distributors List

Table 75. Neuroblastoma Treatment Drugs Customer List

Table 76. Global Neuroblastoma Treatment Drugs Sales Forecast by Region (2023-2028) & (K Units)

Table 77. Global Neuroblastoma Treatment Drugs Sales Market Forecast by Region

Table 78. Global Neuroblastoma Treatment Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 81. Americas Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Neuroblastoma Treatment Drugs Sales Forecast by Region (2023-2028) & (K Units)

Table 83. APAC Neuroblastoma Treatment Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 85. Europe Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 87. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Neuroblastoma Treatment Drugs Sales Forecast by Type (2023-2028) & (K Units)

Table 89. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Neuroblastoma Treatment Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Neuroblastoma Treatment Drugs Sales Forecast by Application (2023-2028) & (K Units)

Table 93. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Neuroblastoma Treatment Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Application (2023-2028)

Table 96. United Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 97. United Therapeutics Neuroblastoma Treatment Drugs Product Offered

Table 98. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 99. United Therapeutics Main Business

Table 100. United Therapeutics Latest Developments

Table 101. Y-mAbs Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 102. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offered

Table 103. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 104. Y-mAbs Therapeutics Main Business

Table 105. Y-mAbs Therapeutics Latest Developments

Table 106. EUSA Pharma Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 107. EUSA Pharma Neuroblastoma Treatment Drugs Product Offered

Table 108. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 109. EUSA Pharma Main Business

Table 110. EUSA Pharma Latest Developments

Table 111. ANI Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 112. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

Table 113. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 114. ANI Pharmaceuticals Main Business

Table 115. ANI Pharmaceuticals Latest Developments

Table 116. Baxter Healthcare Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 117. Baxter Healthcare Neuroblastoma Treatment Drugs Product Offered

Table 118. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 119. Baxter Healthcare Main Business

Table 120. Baxter Healthcare Latest Developments

Table 121. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 122. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

Table 123. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 124. Ingenus Pharmaceuticals Main Business

Table 125. Ingenus Pharmaceuticals Latest Developments

Table 126. Pfizer Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 127. Pfizer Neuroblastoma Treatment Drugs Product Offered

Table 128. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 129. Pfizer Main Business

Table 130. Pfizer Latest Developments

Table 131. Hikma Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 132. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

Table 133. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 134. Hikma Pharmaceuticals Main Business

Table 135. Hikma Pharmaceuticals Latest Developments

Table 136. Teva Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors

Table 137. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered

Table 138. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 139. Teva Pharmaceuticals Main Business

Table 140. Teva Pharmaceuticals Latest Developments

List of Figures

Figure 1. Picture of Neuroblastoma Treatment Drugs

Figure 2. Neuroblastoma Treatment Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Neuroblastoma Treatment Drugs Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Neuroblastoma Treatment Drugs Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Neuroblastoma Treatment Drugs Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Cyclophosphamide

Figure 10. Product Picture of Dinutuximab

Figure 11. Product Picture of Naxitamab

Figure 12. Product Picture of Doxorubicin Hydrochloride

Figure 13. Product Picture of Vincristine Sulfate

Figure 14. Product Picture of Other

Figure 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Type in 2021

Figure 16. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)

Figure 17. Neuroblastoma Treatment Drugs Consumed in Hospital

Figure 18. Global Neuroblastoma Treatment Drugs Market: Hospital (2017-2022) & (K Units)

Figure 19. Neuroblastoma Treatment Drugs Consumed in Clinic

Figure 20. Global Neuroblastoma Treatment Drugs Market: Clinic (2017-2022) & (K Units)

Figure 21. Neuroblastoma Treatment Drugs Consumed in Other

Figure 22. Global Neuroblastoma Treatment Drugs Market: Other (2017-2022) & (K Units)

Figure 23. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)

Figure 24. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2021

Figure 25. Neuroblastoma Treatment Drugs Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company in 2021

Figure 27. Global Neuroblastoma Treatment Drugs Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region in 2021

Figure 29. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2022)

Figure 30. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region in 2021

Figure 31. Americas Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)

Figure 32. Americas Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)

Figure 33. APAC Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)

Figure 34. APAC Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)

Figure 35. Europe Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)

Figure 36. Europe Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)

Figure 38. Middle East & Africa Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)

Figure 39. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021

Figure 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021

Figure 41. United States Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region in 2021

Figure 46. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Regions in 2021

Figure 47. China Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021

Figure 54. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021

Figure 55. Germany Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021

Figure 62. Egypt Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2021

Figure 68. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs

Figure 69. Industry Chain Structure of Neuroblastoma Treatment Drugs

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...

  • Publish Date: May 29, 2018
  • $5370
World Medical Robotics and Computer - Assisted Surgery Market - Opportunities and Forecasts, 2015 - 2022

The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...

  • Publish Date: May 1, 2016
  • $5370